Table 1.

Characteristics of patients

Discovery phaseValidation phase
IBD-associated neoplasias (n = 25)
Sporadic CRC (n = 88)Healthy controls (n = 39)Sporadic CRC (n = 126)Dysplasias (n = 8)Cancers (n = 17)
Sex
 Male51 (58%)20 (51%)83 (66%)8 (100%)13 (76%)
 Female37 (42%)19 (41%)43 (34%)0 (0%)4 (24%)
Mean age ± SD, y63.2 ± 10.358 ± 766 ± 1157 ± 2065 ± 17
Location
 Distal71 (81%)84 (67%)4 (50%)7 (41%)
 Proximal16 (10%)42 (33%)4 (50%)10 (59%)
 Missing data1 (1%)
Stage
 I–II23 (26%)65 (52%)11 (65%)
 III–IV75 (85%)61 (48%)6 (35%)
Extent of IBD
 Extensive7 (88%)5 (31%)
 Left-sided1 (12%)11 (69%)
 Missing data0 (0%)1 (6%)
Duration of IBD, y9 ± 8.78.8 ± 8.7
Histologic gradea
 HGD0 (0%)
 LGD8 (100%)

NOTE: No significant differences were observed comparing IBD-associated neoplasias (dysplasias and cancers).

Abbreviations: HGD, high-grade dysplasia; LGD, low-grade dysplasia.